Sagimet Biosciences SGMT 深 沪
等待开盘 11-12 09:30:00 美东时间
11.41
+0.520
+4.78%
华盛通- 最 高11.44
- 今 开10.93
- 成交量 179.03万股
- 最 低 10.80
- 昨 收 10.89
- 总市值 8.09亿
- 52周最高 11.449
- 市盈率 静 --
- 换手率 2.52%
- 52周最低 4.50
- 委 比 -58.62%
- 总股本 7090.87万
- 历史最高 20.71
- 量 比 1.65
- 振 幅 5.88%
- 历史最低 1.73
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sagimet Biosciences Highlights Progress in Acne FASN Pipeline
Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has issued an announcement. On Oc...
10-22 19:48
Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner Ascletis Pivotal trial designed to enroll approximately 800 U.S. patients, including 450 adolescents aged...
10-22 19:03
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
Sagimet Biosciences Inc. announced the initiation of the AURORA Phase 3 clinical trial for denifanstat, targeting moderate to severe acne in adults and adolescents aged 12 and older. The trial aims to enroll approximately 800 U.S. patients, with 450 expected to be adolescents. Denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, has shown positive results in China and could address the needs of about 10 million Americans with mode...
10-22 11:00
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.
10-02 21:06
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris. In January, the company shared topline data from the study. Concurrently, the clinical-stage biopharmaceutical firm priced an underwritten public offering ex...
10-01 02:11
Sagimet Biosciences Prices $115M Offer Of 8,750,010 Shares And Warrants At $10.00/Unit
Underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the "Pre-Funded Warrants") at a p...
09-30 18:23
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.
09-24 21:57
